Empowered Funds’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Empowered Funds’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$211K	Buy	+75,996	New	+$307K	﹤0.01%	2219

Other funds holding ZNTL

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Patient Square Capital Menlo Park, California $627M AUM 115.4% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $685M AUM 129.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Empowered Funds's ZNTL Position: Q3 2026 in Review

Empowered Funds opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q3 2026: 75,996 shares worth $211K. The stake represents ﹤0.01% of the portfolio and ranks #2219 among its holdings.

81 funds tracked by Wall St. Rank hold ZNTL as of Q3 2026.

Empowered Funds held 75,996 shares of Zentalis Pharmaceuticals worth $211K as of Q3 2026.
Zentalis Pharmaceuticals was a new Empowered Funds position in Q3 2026.
Zentalis Pharmaceuticals made up ﹤0.01% of Empowered Funds's portfolio in Q3 2026, its #2219 holding.
81 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2026.

Based on Empowered Funds's 13F filing for Q3 2026, filed 13 Nov 2026.